Mga Batayang Estadistika
| LEI | 5493003TZPR4B7QO9L49 |
| CIK | 1607245 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Oasmia Pharmaceutical AB
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| April 4, 2022 |
424B3 1 vivesto424b3.htm 424B3 Rule 424(b)(3) File No. 333-205841 Note: Oasmia Pharmaceutical AB has changed its name to Vivesto AB effective April 8, 2022. AMERICAN DEPOSITARY SHARES (Each American Depositary Share represents three deposited Shares) THE BANK OF NEW YORK MELLON AMERICAN DEPOSITARY RECEIPT FOR ORDINARY SHARES OF VIVESTO AB (INCORPORATED UNDER THE LAWS OF THE KINGDOM OF SWEDEN) The |
|
| November 27, 2019 |
Rule 424(b)(3) File No. 333-205841 [Note: This revised form of American Depositary Receipt is being filed to reflect that the correct ratio of Shares per American Depositary Shares of three Shares.] AMERICAN DEPOSITARY SHARES (Each American Depositary Share represents three deposited Shares) THE BANK OF NEW YORK MELLON AMERICAN DEPOSITARY RECEIPT FOR ORDINARY SHARES OF OASMIA PHARMACEUTICAL AB (IN |
|
| November 21, 2019 |
LZRFY / Localiza Rent A Car SA F-6 POS - - FORM F-6 POS As filed with the Securities and Exchange Commission on November 21, 2019. Registration No. 333-205841 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO THE FORM F-6 REGISTRATION STATEMENT under THE SECURITIES ACT OF 1933 For Depositary Shares OASMIA PHARMACEUTICAL AB. (Exact name of issuer of deposited securities as specified in its charter) N/A (Translat |
|
| November 21, 2019 |
EX-1 2 oasmiada.htm FORM OF DEPOSIT AGREEMENT =============================================================== OASMIA PHARMACEUTICAL AB AND THE BANK OF NEW YORK MELLON As Depositary AND OWNERS AND HOLDERS OF AMERICAN DEPOSITARY SHARES Deposit Agreement October 22, 2015 =============================================================== TABLE OF CONTENTS ARTICLE 1. DEFINITIONS 1 SECTION 1.1. American De |
|
| August 23, 2019 |
Rule 424(b)(3) File No. 333-205841 OVERSTAMP: Upon effectiveness of the termination of the Company’s reporting requirements under the Exchange Act, the Company will publish information in English required to maintain the exemption from registration under Rule 12g3-2(b) under the Securities Exchange Act of 1934, as amended, on its Internet web site or through an electronic information delivery syst |
|
| August 23, 2019 |
OASM / Oasmia Pharmaceutical AB 15F-12B - - FORM 15F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15F CERTIFICATION OF A FOREIGN PRIVATE ISSUER’S TERMINATION OF REGISTRATION OF A CLASS OF SECURITIES UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ITS TERMINATION OF THE DUTY TO FILE REPORTS UNDER SECTION 13(a) OR SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37604 OASMIA |
|
| August 21, 2019 |
Exhibit 99.1 Uppsala August 20, 2019 PRESS RELEASE Nomination committee in Oasmia for the 2019 AGM In accordance with the decision at the Annual General Meeting of Oasmia Pharmaceutical AB on September 25, 2018, the two largest shareholders in terms of voting rights who have chosen to participate in the Nomination Committee. Together with the Chairman of the Board constitute they will constitute t |
|
| August 21, 2019 |
OASM / Oasmia Pharmaceutical AB 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2019 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark |
|
| August 15, 2019 |
OASM / Oasmia Pharmaceutical AB 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2019 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark |
|
| August 15, 2019 |
Exhibit 99.1 Uppsala August 15, 2019 PRESS RELEASE Oasmia postpones the release of the Q1 report to 26 September and adjusts its financial calendar The Board of Oasmia has decided to postpone the release of the first quarter report 2019/2020 from 6 September 2019 to 26 September 2019 at 7.30 am CEST. The postponement is a result of a continued heavy workload. The Board of Directors has also decide |
|
| August 12, 2019 |
OASM / Oasmia Pharmaceutical AB 25 - - FORM 25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB NASDAQ Capital Markets (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) Vallon |
|
| August 8, 2019 |
OASM / Oasmia Pharmaceutical AB POS AM - - POS AM As filed with the Securities and Exchange Commission on August 8, 2019 Registration No. |
|
| August 6, 2019 |
OASM / Oasmia Pharmaceutical AB 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2019 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark |
|
| August 6, 2019 |
Exhibit 99.1 Uppsala Aug 2, 2019 PRESS RELEASE Oasmia intends to delist from NASDAQ in the US to reduce complexity and costs Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) announced today that it intends to delist its American Depositary Shares (“ADS”) from the Nasdaq Capital Market (“NASDAQ”) and to deregister and terminate its reporting obligations with the Securities and Exchange Commissi |
|
| August 1, 2019 |
Exhibit 99.1 Uppsala July 31, 2019 PRESS RELEASE New number of shares and votes in Oasmia Pharmaceutical AB (publ) The number of shares and votes in Oasmia Pharmaceutical AB (publ) has increased as a result of Oasmia's largest shareholder Arwidsro's utilization of a total of 24.2 million warrants in accordance with the previously announced agreement between Oasmia and Arwidsro. As a result of the |
|
| August 1, 2019 |
OASM / Oasmia Pharmaceutical AB 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2019 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark wh |
|
| July 9, 2019 |
OASM / Oasmia Pharmaceutical AB 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2019 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark wh |
|
| July 9, 2019 |
EX-99.1 2 tv524922ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Uppsala July 9, 2019 PRESS RELEASE Oasmia discontinues cooperation with former executive chairman Oasmia has today ended the engagement and cooperation with the former executive chairman Julian Aleksov without any further remuneration. This is done in the light of the transactions mentioned in the company's press release on June 28 and the com |
|
| July 9, 2019 |
Exhibit 99.2 Uppsala July 5, 2019 PRESS RELEASE Oasmia and Arwidsro have solved outstanding balances and Arwidsro increases its investment in Oasmia Today an agreement has been made between Oasmia and its largest shareholder Arwidsro. The agreement is made to solve earlier unclear balances and to support the planned commercialization of Oasmia with more capital. Jörgen Olsson, independent Chairman |
|
| July 9, 2019 |
OASM / Oasmia Pharmaceutical AB 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2019 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark wh |
|
| July 9, 2019 |
EX-99.1 2 tv524866ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 July 4, 2019 PRESS RELEASE Oasmia appoints Business Advisory Board Oasmia has appointed a Business Advisory Board with the aim of primarily supporting the commercialization of Apealea and evaluating development and market opportunities for the other product candidates. The members of the Oasmia Business Advisory Board are: Göran Pettersson, Ja |
|
| July 2, 2019 |
EX-99.1 2 tv524723ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Uppsala July 2, 2019 PRESS RELEASE Oasmia appoints new CMO Nina Heldring, PhD, has today been appointed as acting CMO of Oasmia Pharmaceutical AB. Nina Heldring has 20 years of experience with pre-clinical and clinical medical research from renowned academic institutes and the pharmaceutical industry. Previous acting CMO, Sven Rohmann, was app |
|
| July 2, 2019 |
OASM / Oasmia Pharmaceutical AB 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2019 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark wh |
|
| July 2, 2019 |
EX-99.2 3 tv524723ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 July 2, 2019 PRESS RELEASE Oasmia appoints Scientific Advisory Board Oasmia today announces the formation of its Scientific Advisory Board with three key appointments: Professor Rolf Lewensohn, MD, PhD, Hans Grönlund, PhD and Ola Winqvist, MD, PhD. The scientific advisory board will work closely with Oasmia’s Research and Development team. It |
|
| June 28, 2019 |
EX-99.3 4 tv524514ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 Uppsala June 28, 2019 PRESS RELEASE Oasmia announces change of CEO Sven Rohmann, MD PhD MBA, has today been appointed as acting CEO of Oasmia Pharmaceutical AB. He assumes his new role July 1, 2019. Since March 2019 Sven Rohmann has been a member of the Board of Oasmia and since April he has been acting Chief Medical Officer (CMO). He has exte |
|
| June 28, 2019 |
Exhibit 99.1 Uppsala June 28, 2019 PRESS RELEASE Oasmia Pharmaceutical AB (publ) Year-end report for the financial year May 1, 2018 – April 30, 2019 EVENTS IN FOURTH QUARTER · Private placement of approximately MSEK 165 before issue expenses carried out · New Board of Directors elected at Extraordinary General Meeting on March 19 · New Board initiates review of the situation in the company · Manag |
|
| June 28, 2019 |
OASM / Oasmia Pharmaceutical AB 6-K - Current Report of Foreign Issuer - FORM 6-K 6-K 1 tv5245146k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2019 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive off |
|
| June 28, 2019 |
Exhibit 99.4 Uppsala June 28, 2019 PRESS RELEASE The Board of Oasmia has decided to report certain transactions to the Swedish Economic Crime Authority and to appoint a special examiner The Board of Oasmia has decided to report certain suspicious transactions that has been made by the company during several years to the Swedish Economic Crime Authority. In connection with a tax audit in Oasmia tha |
|
| June 28, 2019 |
EX-99.2 3 tv524514ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Oasmia Pharmaceutical AB (publ) Year-end report for the financial year May 1, 2018 – April 30, 2019 EVENTS IN FOURTH QUARTER · Private placement of approximately MSEK 165 before issue expenses carried out · New Board of Directors elected at Extraordinary General Meeting on March 19 · New Board initiates review of the situation in the company · |
|
| June 26, 2019 |
EX-99.1 2 tv524315ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Uppsala 26 June 2019 PRESS RELEASE Oasmia presents full-year report and status in the Board's review through audiocast on June 28 Oasmia will hold an audiocast and telephone conference on Friday 28 June at 09:00 (CET) to present the company's full-year report for the financial year 2018/2019 and the status of the board's previously communicate |
|
| June 26, 2019 |
OASM / Oasmia Pharmaceutical AB 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2019 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark wh |
|
| June 25, 2019 |
OASM / Oasmia Pharmaceutical AB 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2019 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark wh |
|
| June 25, 2019 |
EX-99.1 2 tv524224ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Uppsala 25 June 2019 PRESS RELEASE Two studies finalized in Oasmia Pharmaceutical’s Docecal programme Oasmia Pharmaceutical AB (NASDAQ: OASM) reports on the results from the two clinical studies using Docecal in patients with metastatic breast cancer. Docecal is a newly developed formulation of docetaxel – the active substance in the well esta |
|
| May 20, 2019 |
EX-99.1 2 tv522066ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Uppsala 15 May 2019 PRESS RELEASE Oasmia postpones the release of the Q4 and year-end report to 28 June The Board of Oasmia has decided to postpone the release of the fourth quarter and year-end 2018/2019 report from 5 June 2019 to 28 June 2019. The delay is a result of the ongoing review initiated by the new Board in March 2019. There are a n |
|
| May 20, 2019 |
OASM / Oasmia Pharmaceutical AB 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2019 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark whe |
|
| April 12, 2019 |
Oasmia expands the Management Team EX-99.1 2 tv518602ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 2019-04-10 PRESS RELEASE Oasmia expands the Management Team Oasmia Pharmaceutical AB (NASDAQ: OASM) expands the Management Team in order to directly involve the whole organization in the commercialization of Apealea and other product candidates. Earlier the Management Team was formed only by the CEO, the CFO and the Executive Chairman. The fol |
|
| April 12, 2019 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2019 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark w |
|
| April 4, 2019 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2019 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark w |
|
| April 4, 2019 |
Short report of the status of the review in Oasmia EX-99.1 2 tv518179ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 2019-04-03 PRESS RELEASE Short report of the status of the review in Oasmia Two weeks ago, March 19th, the Extra General Meeting in Oasmia elected a new Board on the initiative of the main owner Arwidsro. The new Board has since then taken control over the Company and started implementing new governance and initiated due diligence of the most |
|
| April 1, 2019 |
Increase in the number of shares and votes in Oasmia Pharmaceutical AB (publ) Exhibit 99.1 2019-03-29 PRESS RELEASE Increase in the number of shares and votes in Oasmia Pharmaceutical AB (publ) The number of shares and votes in Oasmia Pharmaceutical AB (publ) has increased as a result of the directed new share issue carried out in March 2019. Through the directed share issue the number of outstanding shares and votes has increased by 22,948,535 from 201,952,111 to 224,900,6 |
|
| April 1, 2019 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2019 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark w |
|
| April 1, 2019 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2019 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark w |
|
| March 27, 2019 |
CFO of Oasmia, Anders Blom has resigned Exhibit 99.2 2019-03-26 PRESS RELEASE CFO of Oasmia, Anders Blom has resigned Yesterday Oasmia received the resignation of the Company’s CFO Anders Blom. The Board and the CEO have decided to appoint, as acting CFO, Joakim Lindén. Joakim Lindén has long experience from transition processes in listed companies in different roles including CFO positions. Anders Blom will remain at Oasmias disposal f |
|
| March 27, 2019 |
OASM / Oasmia Pharmaceutical AB 6-K (Current Report of Foreign Issuer) 6-K 1 tv5172956k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2019 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) |
|
| March 27, 2019 |
Notification from Oasmia Pharmaceutical AB Exhibit 99.3 2019-03-26 PRESS RELEASE Notification from Oasmia Pharmaceutical AB Uppsala, Sweden, March 26, 2019 – The Swedish Securities Council has today published a statement regarding Oasmia. For statement please click here (only in Swedish). About Oasmia Pharmaceutical AB Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and vete |
|
| March 27, 2019 |
Exhibit 99.1 2019-03-25 PRESS RELEASE Oasmia Pharmaceutical AB receives positive opinion from the European Medicines Agency to add efficacy data to the approved Apealea® product information Uppsala, Sweden, March 25, 2019 – Oasmia Pharmaceutical AB (NASDAQ: OASM) today announce that the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a type II variation appl |
|
| March 25, 2019 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2019 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark w |
|
| March 25, 2019 |
New Board starts reviewing the situation in Oasmia EX-99.1 2 tv516942ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 2019-03-21 PRESS RELEASE New Board starts reviewing the situation in Oasmia March 19th, the Extra General Meeting in Oasmia elected a new Board on the initiative of the main owner Arwidsro. The EGM was well represented with over a hundred participating shareholders and over 400 proxies. Jörgen Olsson was elected as the Chairman of the new Boar |
|
| March 19, 2019 |
Exhibit 99.1 2019-03-19 PRESS RELEASE Oasmia Pharmaceutical AB (publ): Press release from the extraordinary general meeting 19 March 2019 In Oasmia Pharmaceutical AB (publ) (“Oasmia” or the ”Company”) an extraordinary general meeting was held today. The extraordinary general meeting was convened at the request of shareholders representing more than 10 per cent of the shares in the Company to addre |
|
| March 19, 2019 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2019 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark w |
|
| March 6, 2019 |
Oasmia Pharmaceutical Strengthens its Management Team and Organization Exhibit 99.1 2019-03-06 PRESS RELEASE Oasmia Pharmaceutical Strengthens its Management Team and Organization To increase resources and its business development function, Oasmia has employed Anette Sjödin as Executive Vice President to focus on commercialization and business development. The organization is further strengthened by the addition of new Head of Regulatory Affairs, Maria Nilsson Hagber |
|
| March 6, 2019 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2019 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark w |
|
| March 4, 2019 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2019 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark w |
|
| March 4, 2019 |
Oasmia has completed a directed share issue of approximately 165 MSEK Exhibit 99.1 This press release may not be published or distributed, directly or indirectly, in, or to, Australia, Hong Kong, Japan, Canada, New Zeeland, Singapore, South Africa or the USA, or any other country where such measure is wholly or partially subject to legal restrictions. The information in this press release may not be forwarded, reproduced or displayed in a way that is contrary to suc |
|
| March 1, 2019 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2019 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark w |
|
| March 1, 2019 |
Oasmia Pharmaceutical AB (publ) March 1, 2019 Exhibit 99.1 Oasmia Pharmaceutical AB (publ) March 1, 2019 Interim report for the period May 2018 – January 2019 THIRD QUARTER November 1, 2018 – January 31, 2019 · Consolidated net sales amounted to TSEK 1,427 compared to TSEK 656 in the third quarter the previous year · Operating loss was TSEK 26,428 compared to TSEK 25,158 in the third quarter the previous year · Net loss after tax amounted to |
|
| March 1, 2019 |
Exhibit 99.2 Oasmia Pharmaceutical AB (publ) Interim report for the period May 2018 – January 2019 THIRD QUARTER November 1, 2018 – January 31, 2019 · Consolidated net sales amounted to TSEK 1,427 compared to TSEK 656 in the third quarter the previous year · Operating loss was TSEK 26,428 compared to TSEK 25,158 in the third quarter the previous year · Net loss after tax amounted to TSEK 30,260 co |
|
| February 5, 2019 |
NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL) Exhibit 99.1 This is an unofficial in-house translation of the Swedish original. In case of differences the Swedish version shall prevail. press release 2019-02-05 NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL) THE SHAREHOLDERS OF OASMIA PHARMACEUTICAL AB (PUBL) ARE HEREBY GIVEN NOTICE OF THE EXTRAORDINARY GENERAL MEETING ON TUESDAY 19 MARCH 2019, AT 14.00 P.M., AT THE |
|
| February 5, 2019 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2019 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mar |
|
| February 1, 2019 |
Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ) Exhibit 99.1 2019-01-31 PRESS RELEASE Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ) Oasmia Pharmaceutical AB (publ) (”Oasmia” or ”Company” or “Group”) on 18 April 2018 issued a convertible loan with a total nominal amount of MSEK 26. In total circa MSEK 7 of the convertible loan has during January 2019, at the request of convertible loan holders, been converted into s |
|
| February 1, 2019 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2019 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mar |
|
| January 22, 2019 |
Exhibit 99.1 2019-01-22 PRESS RELEASE Oasmia Pharmaceutical AB’s (publ, ”Oasmia”) decision to cancel the extraordinary general meeting on January 25, 2019 Uppsala, Sweden, January 22, 2019 – The proposition on a new board of directors in Oasmia presented by Arwidsro Investment AB and Per Arwidsson (jointly “Arwidsro”) only a short period before the planned general meeting does not comply with Nasd |
|
| January 22, 2019 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2019 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark |
|
| January 22, 2019 |
Oasmia announces that the extraordinary general meeting 25 January 2019 is cancelled 2019-01-21 PRESS RELEASE Oasmia announces that the extraordinary general meeting 25 January 2019 is cancelled Uppsala, Sweden, January 21, 2019 – Oasmia Pharmaceutical AB (publ) (“Oasmia” or the ”Company”) hereby announces that the board of directors of the Company has resolved to cancel the extraordinary general meeting which was to be held 25 January 2019. |
|
| January 22, 2019 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2019 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark |
|
| January 15, 2019 |
Exhibit 99.1 2019-01-15 PRESS RELEASE European Medicines Agency validates Oasmia Pharmaceutical AB’s application to add efficacy data to the approved Apealea® product information Efficacy data from sub-group analysis for Apealea show significant advantage with regards to progression free survival in patients with first relapse. Uppsala, Sweden, January 15, 2019 – Oasmia Pharmaceutical AB (NASDAQ: |
|
| January 15, 2019 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2019 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark |
|
| December 19, 2018 |
NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL) Exhibit 99.1 This is an unofficial in-house translation of the Swedish original. In case of differences the Swedish version shall prevail. PRESS RELEASE 2018-12-14 NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL) THE SHAREHOLDERS OF OASMIA PHARMACEUTICAL AB (PUBL) ARE HEREBY GIVEN NOTICE OF THE EXTRAORDINARY GENERAL MEETING ON FRIDAY 25 JANUARY 2019, AT 14.00 P.M., AT THE |
|
| December 19, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mar |
|
| December 17, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mar |
|
| December 17, 2018 |
Exhibit 99.1 2018-12-17 PRESS RELEASE Clarification from the Board of Directors and Management of Oasmia Pharmaceutical AB (publ), “Oasmia” due to Per Arwidsson’s and Arwidsro Investment AB’s request for convening an Extraordinary General Meeting In 2017 and 2018, Oasmia has had a number of successful developments. Oasmia is currently in a phase where it has positive momentum with many ongoing act |
|
| December 14, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mar |
|
| December 14, 2018 |
NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL) Exhibit 99.1 This is an unofficial in-house translation of the Swedish original. In case of differences the Swedish version shall prevail. PRESS RELEASE 2018-12-14 NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL) THE SHAREHOLDERS OF OASMIA PHARMACEUTICAL AB (PUBL) ARE HEREBY GIVEN NOTICE OF THE EXTRAORDINARY GENERAL MEETING ON FRIDAY 25 JANUARY 2019, AT 14.00 P.M., AT THE |
|
| November 30, 2018 |
Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ) Exhibit 99.1 2018-11-30 PRESS RELEASE Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ) Uppsala, Sweden, November 30, 2018 – Oasmia Pharmaceutical AB (publ) (”Oasmia” or ”Company” or “Group”) on 29 November 2017 and on 7 September 2018, issued convertible loans with total nominal amount of MSEK 28 and MSEK 35.2 respectively. In total circa MSEK 21.3 of the convertible loa |
|
| November 30, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mar |
|
| November 30, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mar |
|
| November 30, 2018 |
November 30, 2018 Uppsala, Sweden Exhibit 99.2 Oasmia Pharmaceutical AB develops, manufactures, markets and sells a new generation of drugs within human and veterinary oncology. Product development aims to produce novel formulations based on well-established cytostatics which, in comparison with current alternatives, display improved properties, a reduced side-effect profile and expanded therapeutic areas. Product development is b |
|
| November 30, 2018 |
Oasmia Pharmaceutical AB (publ) Exhibit 99.1 Oasmia Pharmaceutical AB (publ) Interim report for the period May – October 2018 SECOND QUARTER August 1 – October 31, 2018 · Consolidated net sales amounted to TSEK 158 compared to TSEK 1,651 in the second quarter the previous year · Operating loss was TSEK 22,627 compared to TSEK 22,129 in the second quarter the previous year · Net loss after tax amounted to TSEK 60,982 compared to |
|
| November 29, 2018 |
Exhibit 99.1 2018-11-29 PRESS RELEASE Oasmia Pharmaceutical AB announces new agreement with Baxter Oncology GmbH for global commercial manufacturing of Apealea® Uppsala, Sweden, November 29, 2018 – Oasmia Pharmaceutical AB (Nasdaq: OASM) today announce that the company has signed a new five-year contract with Baxter BioPharma Solutions for global commercial manufacturing of Apealea. Technology and |
|
| November 29, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mar |
|
| November 28, 2018 |
Exhibit 99.1 2018-11-28 PRESS RELEASE Oasmia intends to issue notice to an extraordinary general meeting at the request of a shareholder and announces that it is subject to legal proceedings with a major shareholder concerning the company’s warrants 2018/2019 Uppsala, Sweden, November 28, 2018 – Oasmia Pharmaceutical AB (publ) (“Oasmia”) hereby announces that Oasmia’s largest shareholder, Arwidsro |
|
| November 28, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mar |
|
| November 27, 2018 |
Exhibit 99.1 2018-11-22 PRESS RELEASE Oasmia Pharmaceutical Receives Approval from European Commission for Apealea® (paclitaxel micellar) in the European Union Apealea is approved in the European Union for treatment of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer in combination with carboplatin in first relapse Uppsala, Sweden, November 22, 2018 |
|
| November 27, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mar |
|
| November 20, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mar |
|
| November 20, 2018 |
New U.S. patent related to Oasmia Pharmaceutical’s nanotechnology platform XR17 has been granted Exhibit 99.1 2018-11-20 PRESS RELEASE New U.S. patent related to Oasmia Pharmaceutical’s nanotechnology platform XR17 has been granted Uppsala, Sweden, November 20, 2018 – Oasmia Pharmaceutical AB (Nasdaq: OASM) announces that the United States Patent and Trademark Office (USPTO) has issued a notification of allowance of a patent for its unique nanotech method to produce pharmaceutical formulation |
|
| November 1, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mar |
|
| November 1, 2018 |
Oasmia completes a private placement of new convertible instruments in the amount SEK 80 million Exhibit 99.1 2018-11-01 PRESS RELEASE Oasmia completes a private placement of new convertible instruments in the amount SEK 80 million Uppsala, Sweden, November 1, 2018 – Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of a convertible loan in the total amount of SEK 80,000,000 with an interest rate of 5 per cent per y |
|
| November 1, 2018 |
OASM / Oasmia Pharmaceutical AB 6-K (Current Report of Foreign Issuer) 6-K 1 tv5060256k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive offic |
|
| November 1, 2018 |
Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ) Exhibit 99.1 2018-10-31 Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ) Uppsala, Sweden October 31, 2018 – Oasmia Pharmaceutical AB (publ) (”Oasmia” or ”Company” or “Group”) on 29 November 2017, on 18 April 2018 and on 7 September 2018, issued convertible loans with total nominal amount of MSEK 28, MSEK 26 and MSEK 35.2 respectively. In total circa MSEK 26.9 of the conv |
|
| October 3, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark |
|
| October 3, 2018 |
Exhibit 99.1 2018-10-03 PRESS RELEASE Oasmia Presents Positive Efficacy and Safety Data for Doxophos Vet in Treatment of Naïve Dogs with Lymphoma Overall response rate data from the (RXE[1]) Phase II study conducted in the US and Sweden met its primary end points and treatment with Doxophos Vet was generally well tolerated. Oasmia’s assessment is that the positive safety and efficacy data will be |
|
| October 1, 2018 |
Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ) Exhibit 99.1 2018-09-30 Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ) Uppsala, Sweden September 30, 2018 – Oasmia Pharmaceutical AB (publ) (”Oasmia” or ”Company” or “Group”) on 18 April 2018 issued a convertible loan with a total nominal amount of MSEK 26. In total MSEK 14 of the convertible loan have during September 2018, at the request of convertible loan holders, |
|
| October 1, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark |
|
| September 25, 2018 |
Annual General Meeting of Oasmia Pharmaceutical AB (publ) held on 25 September 2018 Exhibit 99.1 2018-09-25 PRESS RELEASE Annual General Meeting of Oasmia Pharmaceutical AB (publ) held on 25 September 2018 Oasmia Pharmaceutical AB (publ) held its annual general meeting on Tuesday 25 September 2018. The following main resolutions were passed at the meeting. Adoption of balance sheets and profit and loss accounts It was resolved to adopt the profit and loss account and balance shee |
|
| September 25, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check ma |
|
| September 24, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check ma |
|
| September 24, 2018 |
Exhibit 99.1 2018-09-21 PRESS RELEASE Oasmia Pharmaceutical Receives Positive CHMP Opinion for Apealea® (paclitaxel micellar) in the European Union Apealea receives positive CHMP opinion in the European Union for treatment of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer in combination with carboplatin in first relapse Uppsala, Sweden, September |
|
| September 18, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check ma |
|
| September 18, 2018 |
Update regarding the Market Authorization Application of Apealea in the European Union Exhibit 99.1 2018-09-18 PRESS RELEASE Update regarding the Market Authorization Application of Apealea in the European Union Uppsala, Sweden, September 18, 2018 – With reference to yesterday’s communicated agenda for this week’s meeting by the Committee for Medicinal Products for Human Use (CHMP), the European Medicines Agency (EMA) has informed Oasmia Pharmaceutical that no oral explanation will |
|
| September 14, 2018 |
OASM / Oasmia Pharmaceutical AB 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN |
|
| September 14, 2018 |
Exhibit 13.1 PRINCIPAL EXECUTIVE OFFICER CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 In connection with this Annual Report of Oasmia Pharmaceutical AB (the “Company”) on Form 20-F for the year ended April 30, 2018 as filed with the Securities and Exchange Commission (the “SEC”) on or about the date hereof (the “Report”), I, Mikael Asp, Chief Executive Officer of the Company, certify, pursuant |
|
| September 14, 2018 |
Exhibit 12.1 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER I, Mikael Asp, certify that: 1. I have reviewed this annual report on Form 20-F of Oasmia Pharmaceutical AB; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were |
|
| September 14, 2018 |
Letter from Ernst & Young AB to Securities and Exchange Commission dated September 14, 2018. Exhibit 15.1 AUDITOR’S CONFIRMATION OF STATEMENTS IN ITEM 16.F September 14, 2018 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 16F of Form 20-F dated September 14, 2018, of Oasmia Pharmaceutical AB and are in agreement with the statements contained in paragraphs two and three therein. We have no basis to agree or disagree with o |
|
| September 14, 2018 |
Exhibit 12.2 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER I, Anders Blom, certify that: 1. I have reviewed this annual report on Form 20-F of Oasmia Pharmaceutical AB; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements wer |
|
| September 14, 2018 |
Exhibit 13.2 PRINCIPAL EXECUTIVE OFFICER CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 In connection with this Annual Report of Oasmia Pharmaceutical AB (the “Company”) on Form 20-F for the year ended April 30, 2018 as filed with the Securities and Exchange Commission (the “SEC”) on or about the date hereof (the “Report”), I, Anders Blom, Chief Financial Officer of the Company, certify, pursuan |
|
| September 7, 2018 |
Oasmia completes a private placement of new convertible instruments in the amount SEK 35.2 million Exhibit 99.1 2018-09-07 PRESS RELEASE Oasmia completes a private placement of new convertible instruments in the amount SEK 35.2 million Uppsala, Sweden, September 7, 2018 – Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of a convertible loan in the total amount of SEK 35,200,000 with an interest rate of 8 per cent pe |
|
| September 7, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check ma |
|
| August 31, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB. (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark |
|
| August 31, 2018 |
Exhibit 99.2 Oasmia Pharmaceutical AB develops, manufactures, markets and sells a new generation of drugs within human and veterinary oncology. Product development aims to produce novel formulations based on well-established cytostatics which, in comparison with current alternatives, display improved properties, a reduced side-effect profile and expanded therapeutic areas. Product development is b |
|
| August 31, 2018 |
Oasmia Pharmaceutical AB (publ) Exhibit 99.1 Oasmia Pharmaceutical AB (publ) Interim report for the period May – July 2018 FIRST QUARTER May 1 – July 31, 2018 · Consolidated net sales amounted to TSEK 128 compared to TSEK 20 in the first quarter the previous year · Operating loss was TSEK 26,572 compared to TSEK 28,421 in the first quarter the previous year · Net loss after tax amounted to TSEK 31,102 compared to TSEK 31,713 in |
|
| August 31, 2018 |
OASM / Oasmia Pharmaceutical AB NT 20-F SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-37604 NOTIFICATION OF LATE FILING ¨ Form 10-K x Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: April 30, 2018 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form 20-F ¨ Transition Report on Form N-SAR ¨ Transition Rep |
|
| August 24, 2018 |
NOTICE OF ANNUAL GENERAL MEETING IN OASMIA PHARMACEUTICAL AB Exhibit 99.1 This is an unofficial in-house translation of the Swedish original. In case of differences the Swedish version shall prevail. press release 2018-08-24 NOTICE OF ANNUAL GENERAL MEETING IN OASMIA PHARMACEUTICAL AB THE SHAREHOLDERS OF OASMIA PHARMACEUTICAL AB ARE HEREBY GIVEN NOTICE OF THE ANNUAL GENERAL MEETING ON TUESDAY 25 SEPTEMBER 2018, AT 14:00 CET, AT THE OFFICES OF THE COMPANY, V |
|
| August 24, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark |
|
| August 24, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark |
|
| August 24, 2018 |
Oasmia Pharmaceutical publishes the Annual Report for 2017/2018 Exhibit 99.1 2017-08-24 PRESS RELEASE Oasmia Pharmaceutical publishes the Annual Report for 2017/2018 Oasmia Pharmaceutical’s Annual Report for the fiscal year 2017/2018 is now available at the company’s website, www.oasmia.com. For further information, please contact: Anders Blom, CFO Tel : +46 (0)18 – 50 54 40 E-mail: [email protected] About Oasmia Pharmaceutical AB Oasmia Pharmaceutical AB |
|
| July 31, 2018 |
Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ) Exhibit 99.1 2018-07-31 PRESS RELEASE Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ) Uppsala, Sweden, July 31, 2018 – Oasmia Pharmaceutical AB (publ) (”Oasmia”) on the 29 November 2017 issued a convertible loan with a total nominal amount of MSEK 28. In total MSEK 9 of the convertible loan have during July, at the request of convertible loan holders, been converted int |
|
| July 31, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark wh |
|
| July 27, 2018 |
Status of the Market Authorisation Application of Apealea in the European Union Exhibit 99.2 2018-07-27 PRESS RELEASE Status of the Market Authorisation Application of Apealea in the European Union Uppsala, Sweden, July 27, 2018 – Oasmia Pharmaceutical AB hereby issues a notification that contrary to what was anticipated in the draft agenda for this month’s meeting by the Committee for Medicinal Products for Human Use (CHMP), there was no oral explanation and opinion this mon |
|
| July 27, 2018 |
Status of Orphan designation of Apealea in the European Union Exhibit 99.1 2018-07-27 PRESS RELEASE Status of Orphan designation of Apealea in the European Union Uppsala, Sweden, July 27, 2018 – Oasmia Pharmaceutical AB (NASDAQ: OASM) herewith announces that Apealea was designated as an orphan medicine by the European Commission in 2006 and alongside the procedure of the application for assessing a Market Authorization, the Committee for Orphan Medicinal Pro |
|
| July 27, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark wh |
|
| June 8, 2018 |
OASM / Oasmia Pharmaceutical AB 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark wh |
|
| June 8, 2018 |
Oasmia Pharmaceutical AB (publ) Exhibit 99.1 Oasmia Pharmaceutical AB (publ) Year-end report for the financial year May 1, 2017 – April 30, 2018 FOURTH QUARTER February 1, 2018 – April 30, 2018 · Consolidated net sales amounted to TSEK 843 compared to TSEK 44 in the fourth quarter the previous year · Operating loss was TSEK 28,017 compared to TSEK 37,411 in the fourth quarter the previous year · Net loss after tax amounted to TS |
|
| June 8, 2018 |
Exhibit 99.2 Oasmia Pharmaceutical AB develops, manufactures, markets and sells a new generation of drugs within human and veterinary oncology. Product development aims to produce novel formulations based on well-established cytostatics which, in comparison with current alternatives, display improved properties, a reduced side-effect profile and expanded therapeutic areas. Product development is b |
|
| May 31, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark whe |
|
| May 31, 2018 |
Nexttobe Extends Loan to Oasmia Pharmaceutical Exhibit 99.1 2018-05-30 PRESS RELEASE Nexttobe Extends Loan to Oasmia Pharmaceutical Uppsala, Sweden, May 30, 2018 – Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology announced today that Nexttobe AB has extended its loan to the company. The current loan from Nexttobe amounts to MSEK 102.4 excluding accrued interest and was due o |
|
| May 22, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark whe |
|
| May 22, 2018 |
EX-99.1 2 tv494717ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 2018-05-21 PRESS RELEASE Oasmia Pharmaceutical Completes Spin-off of Veterinary Oncology Assets to Wholly Owned US Subsidiary, AdvaVet, Inc. Uppsala, Sweden, May 21, 2018 – Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, today announced the completed transfer of assets int |
|
| May 22, 2018 |
OASM / Oasmia Pharmaceutical AB CORRESP OASMIA PHARMACEUTICAL AB Vallongstan 1 752 28, Uppsala, Sweden May 22, 2018 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| May 21, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark whe |
|
| May 21, 2018 |
Exhibit 99.1 2018-05-17 PRESS RELEASE Results from Oasmia Pharmaceutical’s phase III study will be presented at ASCO annual meeting in June Oasmia Pharmaceutical AB announce that follow-up results from the completed phase III study with Apealea® for treatment of ovarian cancer will be presented at the 2018 ASCO Annual Meeting in Chicago. Uppsala, Sweden, May 17, 2018 - ASCO (American Society of Cl |
|
| May 18, 2018 |
OASM / Oasmia Pharmaceutical AB F-3/A As filed with the Securities and Exchange Commission on May 18, 2018 Registration No. |
|
| April 30, 2018 |
OASM / Oasmia Pharmaceutical AB F-3 As filed with the Securities and Exchange Commission on April 30, 2018 Registration No. |
|
| April 25, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark w |
|
| April 25, 2018 |
Notification from Oasmia Pharmaceutical AB Exhibit 99.1 2018-04-24 PRESS RELEASE Notification from Oasmia Pharmaceutical AB Uppsala, Sweden, April 24, 2018 – Oasmia Pharmaceutical AB hereby issues a notification regarding the issuance of the agenda for EMA’s CHMP meeting April 23 – 26. Instead of the announced oral explanation, Oasmia will respond to outstanding issues in writing following a 30-day clock stop. Link to the agenda: http://ww |
|
| April 20, 2018 |
Exhibit 99.1 2018-04-19 PRESS RELEASE Oasmia has completed a private placement of new convertible instruments in a total amount of SEK 26,000,000 Uppsala, Sweden April 19, 2018 – Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of a convertible loan in the amount of SEK 26,000,000 with an interest rate of 8 per cent per |
|
| April 20, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark w |
|
| April 11, 2018 |
Exhibit 12.1 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER I, Mikael Asp, certify that: 1. I have reviewed this annual report on Form 20-F/A (Amendment No. 2) of Oasmia Pharmaceutical AB; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which |
|
| April 11, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 20-F/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 2 TO FORM 20-F (Mark One) ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF TH |
|
| April 11, 2018 |
Exhibit 12.2 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER I, Anders Blom, certify that: 1. I have reviewed this annual report on Form 20-F/A (Amendment No. 2) of Oasmia Pharmaceutical AB; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which |
|
| March 28, 2018 |
OASM / Oasmia Pharmaceutical AB CORRESP March 28, 2018 Securities and Exchange Commission Division of Corporate Finance Office of Healthcare and Insurance 100 F Street, NE Washington, DC 20549 Attn: Vanessa Robertson Re: Oasmia Pharmaceutical AB Form 20-F for the Fiscal Year Ended April 30, 2017 Filed August 24, 2017 File No. |
|
| March 6, 2018 |
Attributable to Parent Company shareholders Exhibit 99.2 Oasmia Pharmaceutical AB develops, manufactures, markets and sells a new generation of drugs within human and veterinary oncology. Product development aims to produce novel formulations based on well-established cytostatics which, in comparison with current alternatives, display improved properties, a reduced side-effect profile and expanded therapeutic areas. Product development is b |
|
| March 6, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB. (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark |
|
| March 6, 2018 |
Oasmia Pharmaceutical AB (publ) Exhibit 99.1 Oasmia Pharmaceutical AB (publ) Interim report for the period May 2017 – January 2018 Commercial focus and lower cost base THIRD QUARTER November 1, 2017 – January 31, 2018 · Consolidated net sales amounted to TSEK 656 compared to TSEK 36 in the third quarter the previous year · The operating loss was TSEK 25,158 compared to TSEK 34,861 in the third quarter the previous year · The net |
|
| February 23, 2018 |
OASM / Oasmia Pharmaceutical AB CORRESP February 23, 2018 Securities and Exchange Commission Division of Corporate Finance Office of Healthcare and Insurance 100 F Street, NE Washington, DC 20549 Attn: Vanessa Robertson Re: Oasmia Pharmaceutical AB Form 20-F for the Fiscal Year Ended April 30, 2017 Filed August 24, 2017 File No. |
|
| February 21, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mar |
|
| February 21, 2018 |
Oasmia Pharmaceutical’s Docecal program achieves significant development milestone Exhibit 99.1 2018-02-19 PRESS RELEASE Oasmia Pharmaceutical?s Docecal program achieves significant development milestone Oasmia Pharmaceutical AB announces that all patients have been treated in the two ongoing studies with Docecal in metastatic breast cancer. Uppsala, Sweden, February 19, 2018 ? Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and vet |
|
| February 14, 2018 |
OASM / Oasmia Pharmaceutical AB / Nordnet Pensionsfoersaekring AB - FORM SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) Information to Be Included in Statements Filed Pursuant to Rules 13d-1 (b), (c), and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2 (Amendment No. 2)* Oasmia Pharmaceutical AB (Name of Issuer) Common Stock (Title of Class of Securities) SE0000722365 (ISIN Number) December 31, 2017 (Date of Event which |
|
| January 25, 2018 |
Directed issue of warrants in Oasmia Pharmaceutical AB Exhibit 99.1 2018-01-24 PRESS RELEASE Directed issue of warrants in Oasmia Pharmaceutical AB Uppsala, Sweden, January 24, 2018 - The board of directors of Oasmia Pharmaceutical AB (publ) (?Oasmia? or the ?Company?) has resolved on a directed issue of no more than 34,838,709 warrants. Subsequently, all warrants have been subscribed for, of which Arwidsro Investment AB has subscribed for 24,193,548 |
|
| January 25, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark |
|
| January 2, 2018 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2018 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark |
|
| January 2, 2018 |
Oasmia Pharmaceutical Secures Financing of 108 MSEK Exhibit 99.1 2018-01-02 PRESS RELEASE Oasmia Pharmaceutical Secures Financing of 108 MSEK Uppsala, January 2, 2018 - Oasmia Pharmaceutical AB (publ) (?Oasmia? or the ?Company?) a developer of a new generation of drugs within human and veterinary oncology, has agreed to a loan totalling 108 million SEK, of which 75 million SEK will come from Oasmia?s main shareholder Arwidsro Investment AB (?Arwids |
|
| December 12, 2017 |
Oasmia Pharmaceutical receives marketing approval for Paclical® in Kazakhstan Exhibit 99.1 2017-12-11 PRESS RELEASE Oasmia Pharmaceutical receives marketing approval for Paclical? in Kazakhstan Uppsala, Sweden, December 11, 2017 ? Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, announced today that it has received marketing approval for Paclical in Kazakhstan. Paclical is the first water-soluble cancer |
|
| December 12, 2017 |
OASM / Oasmia Pharmaceutical AB 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mar |
|
| December 6, 2017 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mar |
|
| December 6, 2017 |
Exhibit 99.2 Oasmia Pharmaceutical AB develops, manufactures, markets and sells a new generation of drugs within human and veterinary oncology. Product development aims to produce novel formulations based on well-established cytostatics which, in comparison with current alternatives, display improved properties, a reduced side-effect profile and expanded therapeutic areas. Product development is b |
|
| December 6, 2017 |
Oasmia Pharmaceutical AB (publ) Exhibit 99.1 Oasmia Pharmaceutical AB (publ) Interim report for the period May ? October 2017 Increased focus on commercialization SECOND QUARTER August 1 ? October 31, 2017 ? Consolidated net sales amounted to TSEK 1,651 compared to TSEK 56 in the second quarter the previous year ? The operating loss was TSEK 22,129 compared to TSEK 35,867 in the second quarter the previous year ? The net loss af |
|
| December 6, 2017 |
OASM / Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mar |
|
| December 6, 2017 |
Exhibit 99.1 2017-11-30 PRESS RELEASE Oasmia has completed a private placement of new convertible instruments in a total amount of SEK 28,000,000 Uppsala, Sweden November 30, 2017 ? Oasmia Pharmaceutical AB (publ) (?Oasmia? or the ?Company?) hereby announces that the Company has completed a private placement of a convertible loan in the amount of SEK 28,000,000 with an interest rate of 8 per cent |
|
| October 31, 2017 |
Exhibit 12.2 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER I, Anders Blom, certify that: 1. I have reviewed this annual report on Form 20-F/A (Amendment No. 1) of Oasmia Pharmaceutical AB; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which |
|
| October 31, 2017 |
Exhibit 12.1 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER I, Mikael Asp, certify that: 1. I have reviewed this annual report on Form 20-F/A (Amendment No. 1) of Oasmia Pharmaceutical AB; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which |
|
| October 31, 2017 |
Oasmia Pharmaceutical AB 20-F/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2017 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF TH |
|
| October 31, 2017 |
Exhibit 4.33 [***] INDICATES CONFIDENTIAL PORTION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION SUPPLY AND DISTRIBUTION AGREEMENT This Agreement is made on this 9th day of June 2017 entered into by and between: (1) OASMIA PHARMACEUTICAL AB (?Oasmia?) a corporation under the laws of Sweden and having its principal office at Vallo |
|
| October 4, 2017 |
Oasmia Pharmaceutical AB Announces Resignation of its Chief Financial Officer Exhibit 99.1 2017-10-04 PRESS RELEASE Oasmia Pharmaceutical AB Announces Resignation of its Chief Financial Officer Uppsala, Sweden, October 4, 2017 - Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology has announced that the Company?s Chief Financial Officer, Fredrik 6-KGynnerstedt, has decided in mutual agreement with the Company |
|
| October 4, 2017 |
Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark |
|
| October 3, 2017 |
Nexttobe Extends Loan to Oasmia Pharmaceutical Exhibit 99.1 2017-10-02 PRESS RELEASE Nexttobe Extends Loan to Oasmia Pharmaceutical Uppsala, Sweden, October 2, 2017 ? Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology announced today that Nexttobe AB has extended its loan to the company. The current loan from Nexttobe amounts to MSEK 102.4 and was due on September 30, 2017. In |
|
| October 3, 2017 |
Oasmia Pharmaceutical AB 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark |
|
| October 3, 2017 |
Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ) Exhibit 99.1 2017-09-29 Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ) Uppsala, Sweden September 29, 2017 ? Oasmia Pharmaceutical AB (publ) (?Oasmia? or ?Company? or ?Group?) has, as has been previously announced, carried out a rights issue. The shares in the last of the registrations have now been registered with the Swedish Companies Registration Office and have been |
|
| October 3, 2017 |
Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark |
|
| September 26, 2017 |
Annual General Meeting of Oasmia Pharmaceutical AB (publ) Exhibit 99.1 2017-09-25 PRESS RELEASE Annual General Meeting of Oasmia Pharmaceutical AB (publ) held on 25 September 2017 Oasmia Pharmaceutical AB (publ) held its AGM on Monday, 25 September 2017. The main resolutions passed at the meeting were as follows. Adoption of balance sheets and profit and loss accounts It was resolved at the meeting to adopt the profit and loss account and balance sheet, |
|
| September 26, 2017 |
Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check ma |
|
| September 21, 2017 |
Supplementary proposals of the Nomination Committee for the 2017 Annual General Meeting Exhibit 99.1 2017-09-21 PRESS RELEASE Supplementary proposals of the Nomination Committee for the 2017 Annual General Meeting For the AGM on September 25, 2017, the Board of Oasmia Pharmaceutical AB has been informed by the company's Nomination Committee of the following. The Nomination Committee proposes that the Board to be composed of five directors elected at the AGM, with no alternates, for t |
|
| September 21, 2017 |
Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check ma |
|
| September 12, 2017 |
Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check ma |
|
| September 12, 2017 |
Notification from Oasmia Pharmaceutical AB Exhibit 99.1 2017-09-11 PRESS RELEASE Notification from Oasmia Pharmaceutical AB Uppsala, Sweden, September 11, 2017 ? Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, hereby issues a notification regarding the issuance of the agenda for EMA:s CHMP meeting September 11 ? 14. Oasmia has asked for a clock-stop to further respond |
|
| September 5, 2017 |
Exhibit 99.2 Oasmia Pharmaceutical AB develops, manufactures, markets and sells a new generation of drugs within human and veterinary oncology. Product development aims to produce novel formulations based on well-established cytostatics which, in comparison with current alternatives, display improved properties, a reduced side-effect profile and expanded therapeutic areas. Product development is b |
|
| September 5, 2017 |
Oasmia Pharmaceutical AB 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check ma |
|
| September 5, 2017 |
Exhibit 99.1 Oasmia Pharmaceutical AB (publ) September 1, 2017 Interim report for the period May ? July 2017 Doxophos approved in Russia FIRST QUARTER May 1 ? July 31, 2017 ? Consolidated net sales amounted to TSEK 20 compared to TSEK 36 in the first quarter previous year ? Operating loss was TSEK 28,421 compared to TSEK 32,343 in the first quarter previous year ? Net loss after tax amounted to TS |
|
| August 31, 2017 |
Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ) Exhibit 99.1 2017-08-31 Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ) Uppsala, Sweden August 31, 2017 ? Oasmia Pharmaceutical AB (publ) (?Oasmia? or ?Company? or ?Group?) has, as has been previously announced, carried out a rights issue. The main part of the shares in the rights issue have been registered with the Swedish Companies Registration Office and have been re |
|
| August 31, 2017 |
Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark |
|
| August 28, 2017 |
NOTICE OF ANNUAL GENERAL MEETING IN OASMIA PHARMACEUTICAL AB Exhibit 99.1 This is an unofficial in-house translation of the Swedish original. In case of differences the Swedish version shall prevail. press release 2017-08-25 NOTICE OF ANNUAL GENERAL MEETING IN OASMIA PHARMACEUTICAL AB The shareholders of Oasmia Pharmaceutical AB are hereby given notice of the ANNUAL general meeting on 25 september 2017, at 10.00 a.m., at the offices of the company, Vallonga |
|
| August 28, 2017 |
Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark |
|
| August 24, 2017 |
Exhibit 4.33 [***] INDICATES CONFIDENTIAL PORTION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION SUPPLY AND DISTRIBUTION AGREEMENT This Agreement is made on this 9th day of June 2017 entered into by and between: (1) OASMIA PHARMACEUTICAL AB (?Oasmia?) a corporation under the laws of Sweden and having its principal office at Vallo |
|
| August 24, 2017 |
CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER Exhibit 12.1 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER I, Mikael Asp, certify that: 1. I have reviewed this annual report on Form 20-F of Oasmia Pharmaceutical AB; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were |
|
| August 24, 2017 |
Exhibit 13.1 PRINCIPAL EXECUTIVE OFFICER CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 In connection with this Annual Report of Oasmia Pharmaceutical AB (the ?Company?) on Form 20-F for the year ended April 30, 2017 as filed with the Securities and Exchange Commission (the ?SEC?) on or about the date hereof (the ?Report?), I, Mikael Asp, Chief Executive Officer of the Company, certify, pursuant |
|
| August 24, 2017 |
Exhibit 13.2 PRINCIPAL EXECUTIVE OFFICER CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 In connection with this Annual Report of Oasmia Pharmaceutical AB (the ?Company?) on Form 20-F for the year ended April 30, 2017 as filed with the Securities and Exchange Commission (the ?SEC?) on or about the date hereof (the ?Report?), I, Fredrik Gynnerstedt, Chief Financial Officer of the Company, certify, |
|
| August 24, 2017 |
Exhibit 4.32 [***] INDICATES CONFIDENTIAL PORTION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION SALE AND PURCHASE AGREEMENT DATE: October 2016, (the “Agreement Date”) PARTIES: (A) Karo Pharma AB, Nybrokajen 7, 111 48 Stockholm, Sweden, a company incorporated in Sweden with registered number 556309-3359, (the “Seller”); and (B) O |
|
| August 24, 2017 |
CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER Exhibit 12.2 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER I, Fredrik Gynnerstedt, certify that: 1. I have reviewed this annual report on Form 20-F of Oasmia Pharmaceutical AB; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statem |
|
| August 24, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN |
|
| August 15, 2017 |
Oasmia Pharmaceutical AB 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark |
|
| August 15, 2017 |
Oasmia Pharmaceutical receives market approval for its Anti-Cancer Drug Doxophos® in Russia Exhibit 99.1 2017-08-08 PRESS RELEASE Oasmia Pharmaceutical receives market approval for its Anti-Cancer Drug Doxophos? in Russia Uppsala, Sweden, August 8, 2017 ? Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, announced today that it has received marketing approval of Doxophos in Russia, a key milestone following the recentl |
|
| August 2, 2017 |
Oasmia Pharmaceutical AB POS AM As filed with the Securities and Exchange Commission on August 2, 2017 Registration No. |
|
| July 10, 2017 |
The Oasmia Pharmaceutical Annual Report is now published Exhibit 99.1 2017-07-07 PRESS RELEASE The Oasmia Pharmaceutical Annual Report is now published The Oasmia Annual Report for the fiscal year 2016/2017 is now available at the company website www.oasmia.com. For more information, please contact: Fredrik Gynnerstedt, CFO Tel : +4618 ? 50 54 40 E-mail: [email protected] About Oasmia Pharmaceutical AB Oasmia Pharmaceutical AB develops, man |
|
| July 10, 2017 |
Exhibit 99.2 CONTENTS YEAR IN BRIEF 3 HISTORY 3 CEO?S COMMENTS 4 THE SHARE 6 PRODUCTION 8 XR17 9 RESEARCH, DEVELOPMENT AND PROJECT PORTFOLIO 10 MARKET 14 PHARMACEUTICALS AND AUTHORITIES 18 COMPETENCE AND EXPERIENCE 20 ADMINISTRATION REPORT 21 Corporate Governance Report 2016/2017 31 The Board 35 Management 36 Financial statements 37 Notes 47 SIGNING OF THE ANNUAL REPORT 67 AUDITOR?S REPORT 68 QUAR |
|
| July 10, 2017 |
Oasmia Pharmaceutical AB 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB. (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark w |
|
| July 10, 2017 |
Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark wh |
|
| July 10, 2017 |
Oasmia Pharmaceutical AB (publ) announces result of the rights issue Exhibit 99.1 2017-07-07 PRESS RELEASE Oasmia Pharmaceutical AB (publ) announces result of the rights issue Uppsala, Sweden July 7, 2017 ? The subscription period for Oasmia Pharmaceutical AB?s (publ) (?Oasmia? or the ?Company?) rights issue ended on July 5, 2017. The result of the rights issue shows that 23,517,699 shares, representing approximately 46.6 per cent of the shares offered, were subscr |
|
| June 22, 2017 |
Issuance of warrants in Oasmia Pharmaceutical AB (publ) Exhibit 99.1 2017-06-21 PRESS RELEASE Issuance of warrants in Oasmia Pharmaceutical AB (publ) Uppsala, Sweden, June 21, 2017 - Oasmia Pharmaceutical AB (publ) (the ?Company?) resolved, at the Extraordinary General Meeting of the Company on 2 June 2017, to establish two warrant programmes, series 2017:1 and series 2017:2, involving the issuance of a maximum of 3,750,000 and 3,000,000 warrants respe |
|
| June 22, 2017 |
Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark wh |
|
| June 14, 2017 |
Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark wh |
|
| June 14, 2017 |
Exhibit 99.1 2017-06-14 PRESS RELEASE Oasmia Pharmaceutical enters into new exclusive marketing and distribution agreement concerning Russia and other CIS markets Oasmia replaces previous distribution agreement with Hetero Group, a global group of Companies, representing a large operation with expanding capabilities Uppsala, Sweden, June 14, 2017 ? Oasmia Pharmaceutical AB (NASDAQ: OASM) has enter |
|
| June 13, 2017 |
Exhibit 99.1 2017-06-12 PRESS RELEASE Oasmia Pharmaceutical AB (publ): The board of directors resolves upon a rights issue of approximately 163.9 MSEK Uppsala, 12 June, 2017 ? The board of directors of Oasmia Pharmaceutical AB (publ) (?Oasmia? or the ?Company?) announces that the board of directors on 11 June 2017 has resolved to, based on an authorisation from the annual general meeting 26 Septem |
|
| June 13, 2017 |
Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark wh |
|
| June 9, 2017 |
Exhibit 99.2 Oasmia Pharmaceutical AB develops, manufactures, markets and sells a new generation of drugs within human and veterinary oncology. Product development aims to produce novel formulations based on well-established cytostatics which, in comparison with current alternatives, display improved properties, a reduced side-effect profile and expanded therapeutic areas. Product development is b |
|
| June 9, 2017 |
Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB. (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark w |
|
| June 9, 2017 |
Oasmia Pharmaceutical AB (publ) Exhibit 99.1 Oasmia Pharmaceutical AB (publ) Year-end report for the financial year May 1, 2016 ? April 30, 2017 Oasmia separates its veterinary assets Fourth QUARTER February 1 ? April 30, 2017 ? Consolidated net sales amounted to TSEK 44 compared to TSEK 59 in the fourth quarter previous year. ? Operating loss was TSEK 37,411 compared to a loss of TSEK 30,619 in the fourth quarter previous year. |
|
| June 5, 2017 |
Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark wh |
|
| June 5, 2017 |
Report from extra general meeting 2 June 2017 Exhibit 99.1 2017-06-02 PRESS RELEASE Report from extra general meeting 2 June 2017 Oasmia Pharmaceutical AB (publ) registration number 556332-6676 held an extra general meeting on Friday, 2 June 2017. The main content of the resolutions is summarized below. More detailed information about the content of the resolutions is included in the notice and the full proposals for the extra general meeting |
|
| May 31, 2017 |
Oasmia Pharmaceutical AB 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark whe |
|
| May 31, 2017 |
Oasmia Pharmaceutical Issues Clarification Regarding Clinical Study OAS-12DOC-BIO Exhibit 99.1 2017-05-29 PRESS RELEASE Oasmia Pharmaceutical Issues Clarification Regarding Clinical Study OAS-12DOC-BIO Uppsala, Sweden, May 29, 2017 ? Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, hereby issues a clarification regarding the study OAS-12DOC-BIO, of which one clinical site has been closed down as per the EU C |
|
| May 11, 2017 |
Oasmia Pharmaceutical AB 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark whe |
|
| May 11, 2017 |
Oasmia Pharmaceutical to spin-off veterinary assets Exhibit 99.1 2017-05-10 PRESS RELEASE Oasmia Pharmaceutical to spin-off veterinary assets The Company has decided to move its veterinary assets to its US subsidiary and appointed a New York based investment bank to assist in evaluating financial and strategical alternatives for those. New York, May 10, 2017 ? The Board of Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of |
|
| May 2, 2017 |
Increased number of shares and votes in Oasmia Pharmaceutical AB (publ) Exhibit 99.1 2017-05-01 PRESS RELEASE Increased number of shares and votes in Oasmia Pharmaceutical AB (publ) Uppsala, Sweden May 1st, 2017 ? As of May 1st 2017, the total number of shares and votes in Oasmia Pharmaceutical AB (publ) (?Oasmia?) amounts to 126,098,166 shares and votes. The total number of shares and votes has increased as a result of the conversion to shares of the SEK 42,000,193.2 |
|
| May 2, 2017 |
Oasmia Pharmaceutical AB 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark whe |
|
| April 25, 2017 |
Conversion of SEK 42M convertible loan in Oasmia Exhibit 99.1 2017-04-25 PRESS RELEASE Conversion of SEK 42M convertible loan in Oasmia Uppsala, Sweden April 25, 2017 ? Oasmia Pharmaceutical AB (publ) (?Oasmia? or the ?Company?) announce that the convertible loan of SEK 42,000,193.20 (series 2017:1) will be fully converted to shares. In March 2017, Oasmia issued a convertible loan worth SEK 42,000,193.20 which mature on 25 April 2017 unless conv |
|
| April 25, 2017 |
Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark w |
|
| April 18, 2017 |
Exhibit 99.1 2017-04-18 PRESS RELEASE Oasmia completes set-off private placements of new convertibles in the total amount of SEK 26 million with conversion rate of SEK 8.00 Uppsala, Sweden April 18, 2017 ? Oasmia Pharmaceutical AB (publ) (?Oasmia? or the ?Company?) hereby announces that the Company has completed a private placement of a convertible loan in the amount SEK 26,000,000 through a direc |
|
| April 18, 2017 |
Oasmia Pharmaceutical AB 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark w |
|
| March 31, 2017 |
Exhibit 99.1 2017-03-31 PRESS RELEASE Oasmia successfully completes private placements of new convertibles in the total amount of SEK 42 million with conversion rate of SEK 5.95 Uppsala, Sweden March 31, 2017 ? Oasmia Pharmaceutical AB (publ) (?Oasmia? or the ?Company?) hereby announces that the Company has completed a private placement of a convertible loan in the amount SEK 42,000,193 and placed |
|
| March 31, 2017 |
Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark w |
|
| March 21, 2017 |
Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark w |
|
| March 21, 2017 |
Oasmia intends to issue convertible to replace current convertible loan Exhibit 99.1 2017-03-21 PRESS RELEASE Oasmia intends to issue convertible to replace current convertible loan Uppsala, Sweden March 21st, 2017 ? Oasmia Pharmaceutical AB (publ) (?Oasmia? or the ?Company?) intends to issue a new convertible loan to replace the convertible loan (2016:1) in the total nominal amount SEK 28 million, which matures 14 April 2017, through a directed issue to current holde |
|
| March 3, 2017 |
Exhibit 99.2 Oasmia Pharmaceutical AB develops, manufactures, markets and sells a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatic which, in comparison with current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. The product develo |
|
| March 3, 2017 |
Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB. (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark |
|
| March 3, 2017 |
Oasmia Pharmaceutical AB (publ) Interim report for the period May 2016 – January 2017 Exhibit 99.1 Oasmia Pharmaceutical AB (publ) Interim report for the period May 2016 ? January 2017 Strategic changes within Animal Health Division THIRD QUARTER November 1, 2016 ? January 31, 2017 ? Consolidated net sales amounted to TSEK 36 compared to TSEK 6,043 in the third quarter previous year ? Operating loss was TSEK 34,861 compared to a loss of TSEK 23,245 in the third quarter previous yea |
|
| March 2, 2017 |
Exhibit 99.2 2017-03-01 PRESS RELEASE Clarification from the Board of Directors, Company Management and the Principal Shareholders of Oasmia Pharmaceutical AB (publ) Surrounding Anders Lönner’s Withdrawal from the Board of Directors Uppsala, Sweden March 1st, 2017 – Chairman Anders Lönner of Oasmia Pharmaceutical AB (NASDAQ: OASM) has announced his withdrawal from the board of directors, a decisio |
|
| March 2, 2017 |
Oasmia Pharmaceuticals Chairman Anders Lönner Resigns Exhibit 99.1 2017-02-28 PRESS RELEASE Oasmia Pharmaceuticals Chairman Anders L?nner Resigns Uppsala, Sweden February 28, 2017 ? Chairman Anders L?nner of Oasmia Pharmaceutical AB (NASDAQ: OASM) has has informed the Nomination Committee that he does not wish to be re-elected as Chairman and Member of the Board. ?My role as Chairman was not meant to be long-lasting. The Company requires a consistent |
|
| March 2, 2017 |
Oasmia Pharmaceutical AB 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark w |
|
| February 13, 2017 |
OASM / Oasmia Pharmaceutical AB / Alceco International S.A. - SCHEDULE 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240. |
|
| January 24, 2017 |
Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2017 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark |
|
| January 24, 2017 |
Oasmia Pharmaceutical Announces Strategic Move to Bolster Efforts for its Veterinary Division Exhibit 99.1 2017-01-23 PRESS RELEASE Oasmia Pharmaceutical Announces Strategic Move to Bolster Efforts for its Veterinary Division Company intend to move veterinary assets to United States; plans new FDA study Uppsala, January 23, 2017 ? Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, today announced that it plans to move all |
|
| January 9, 2017 |
OASM / Oasmia Pharmaceutical AB / Nordnet Pensionsfoersaekring AB - FORM SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to Be Included in Statements Filed Pursuant to Rules 13d-1 (b), (c), and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2 Oasmia Pharmaceutical AB (Name of Issuer) Common Stock (Title of Class of Securities) SE0000722365 (ISIN Number) December 31, 2016 (Date of Event which Requires Filing of th |
|
| December 22, 2016 |
Exhibit 99.1 2016-12-21 PRESS RELEASE Oasmia Pharmaceutical Reports Positive Results from Study on Weekly Administration of Apealea? (Paclical?) Results from a dose-finding study with weekly administration of Apealea (alternatively branded Paclical in some international regions) in patients with metastatic breast cancer are now available Uppsala, Sweden, December 21, 2016 ? Oasmia Pharmaceutical A |
|
| December 22, 2016 |
Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2016 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mar |
|
| December 7, 2016 |
Oasmia Pharmaceutical AB 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2016 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mar |
|
| December 7, 2016 |
Oasmia Pharmaceutical AB’s Warrant Programs Fully Subscribed EX-99.1 2 v454597ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 2016-12-07 PRESS RELEASE Oasmia Pharmaceutical AB’s Warrant Programs Fully Subscribed Uppsala, Sweden, December 7, 2016 - Oasmia Pharmaceutical (publ.) (”Oasmia” or ”The Company”) announces hereby that the previously announced warrant programs for the Oasmia management and Board of Directors are now fully subscribed. In total, 9,000,000 warrant |
|
| December 5, 2016 |
Oasmia Pharmaceutical AB (publ) Exhibit 99.1 Oasmia Pharmaceutical AB (publ) Interim report for the period May - October 2016 Expanded product portfolio and secured financing SECOND QUARTER August 1 ? October 31, 2016 ? Consolidated net sales amounted to TSEK 56 compared to TSEK 52 in the second quarter previous year ? Operating loss was TSEK 35,867 compared to a loss of TSEK 41,008 in the second quarter previous year ? Net loss |
|
| December 5, 2016 |
Exhibit 99.2 Oasmia Pharmaceutical AB develops, manufactures, markets and sells a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatic which, in comparison with current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. The product develo |
|
| December 5, 2016 |
Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2016 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB. (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check ma |
|
| November 22, 2016 |
Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2016 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mar |
|
| November 22, 2016 |
Communiqué from Extraordinary General Meeting 2016 2016-11-22 PRESS RELEASE Communiqu? from Extraordinary General Meeting 2016 Oasmia Pharmaceutical AB (publ. |
|
| November 2, 2016 |
Nexttobe Extends Loan to Oasmia Pharmaceutical Exhibit 99.2 2016-11-02 PRESS RELEASE Nexttobe Extends Loan to Oasmia Pharmaceutical Uppsala, Sweden, November 2, 2016 ? Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology announced today that Nexttobe AB has extended its loan to the company and also significantly improved the interest terms. The current loan from Nexttobe amounts |
|
| November 2, 2016 |
Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2016 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mar |
|
| November 2, 2016 |
Oasmia Pharmaceutical Announces Change in Ownership Exhibit 99.1 2016-11-01 PRESS RELEASE Oasmia Pharmaceutical Announces Change in Ownership Uppsala, Sweden, November 1, 2016 – Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology announced today that Nexttobe AB has divested its shareholder position in Oasmia in its entirety to a consortium of professional Swedish and international |
|
| November 1, 2016 |
Change in number of shares and voting rights in Oasmia Pharmaceutical AB (publ) Exhibit 99.1 2016-10-31 PRESS RELEASE Change in number of shares and voting rights in Oasmia Pharmaceutical AB (publ) As of October 31, 2016, the total number of shares and voting rights in Oasmia Pharmaceutical AB (publ) (?Oasmia?) is 119,039,310. Oasmia has, in accordance with previously disclosed information, recently completed a directed issue of 8,750,000 shares and an offset issue of 3,080,0 |
|
| November 1, 2016 |
Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2016 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark |
|
| October 26, 2016 |
NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL) 2016-10-26 PRESS RELEASE Oasmia convenes an extraordinary general meeting on the 21 November, 2016. |
|
| October 26, 2016 |
Oasmia Pharmaceutical AB FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2016 Commission File Number: 001-37604 OASMIA PHARMACEUTICAL AB (Name of Registrant) Vallongatan 1, 752 28 Uppsala, Sweden (Address of principal executive office) Indicate by check mark |
|
| October 25, 2016 |
Oasmia successfully completes private placement of SEK 70 million Exhibit 99.5 2016-10-24 PRESS RELEASE Oasmia successfully completes private placement of SEK 70 million Uppsala, Sweden, October 24, 2016 - Oasmia Pharmaceutical AB (publ) (?Oasmia? or the ?Company?) hereby announces that the Company has completed a private placement of 8,750,000 new shares, providing the Company with SEK 70 million before transaction related costs. The private placement, which wa |
|
| October 25, 2016 |
Oasmia Pharmaceutical intends to convene an extraordinary general meeting Exhibit 99.2 2016-10-24 PRESS RELEASE Oasmia Pharmaceutical intends to convene an extraordinary general meeting Uppsala, October 24, 2016 - Oasmia Pharmaceutical intends to convene an extraordinary general meeting to be held on 21 November 2016. Preliminary agenda 1. Election of chairman of the meeting 2. Preparation and approval of the voting list 3. Approval of the agenda 4. Election of one or t |
